Newsroom

CSRxP Blasts Novo Nordisk’s Plans for Prescription Price Hikes

Based on Novo Nordisk’s announcement, it is clear that the company will continue to hike insulin prices, despite the financial burdens already facing patients. “The prescription drug market is clearly broken when limiting yearly price increases to ten percent is considered bighearted,” said John Rother.

Read more

Prices Skyrocket for Drugs Used to Treat Some of the Most Prevalent Health Conditions Facing Americans

“Millions of Americans rely on prescription drugs to get and stay healthy. The challenges of dealing with a health condition are only made worse when pharmaceutical companies take advantage of patients and raising prices where they see an increased market opportunity,” said CSRxP Executive Director John Rother.

Read more

American Diabetes Association calls on Congress to hold hearings on insulin prices

The American Diabetes Association’s board of directors is calling on Congress to hold hearings to investigate dramatic increases in insulin prices and to take action to ensure that people have affordable access to the essential drug.

Read more

Congressional Scrutiny Alone Is Not Enough to Lower Prescription Drug Prices

“The newly-elected Congress has a mandate to pass market-based solutions, such as legislation that would give patients more choices in their medications. Lowering drug prices is the number one healthcare issue for voters — and elected officials are going to continue to hear from their constituents until drug prices are more affordable.”

Read more